Omada Health $OMDA (+0,3%)

Key financial figures (reporting date: 07.05.2026)

• Revenue: $78.0m (+42% YoY vs. $55m in prior year)
• Net loss (GAAP): -3.0 million $ (previous year: -9 million $)
• Adjusted EBITDA: +1.0 million $ (positive for the first time in the first quarter)
• Gross margin: 62% (+4% year-on-year)
• Member base: 1,025,000 (+51% YoY)

Analysis & strategy

• Profitability threshold: Despite typically high costs in Q1, Omada was able to achieve positive adjusted EBITDA through AI-enabled scaling in care. At -$0.05, the loss per share was well above analysts' forecasts (-$0.08).

• GLP-1 & Partnerships: Growth is massively supported by the cooperation with Eli Lilly (Employer Connect) and the integration into programs of large PBMs (Pharmacy Benefit Managers). The integration of GLP-1 companion programs is currently the key growth driver in the B2B sector.

• Forecast increase (FY 2026):
• Revenue: USD 322 - 330 million (previously USD 312 - 322 million)
• Adj. EBITDA: USD 14 - 20 million (previously USD 7 - 15 million)

Critical classification:

The market is currently focusing heavily on the GLP-1 issue. However, the actual fundamental strength lies in the increase in efficiency through automation. While revenue per member is stagnating due to longer retention periods in the system, margins are improving due to lower marginal costs per new user. Investors should monitor whether the dependence on PBM contracts will increase price pressure in the long term.

Earnings date: Thursday, May 7, 2026 after the close of the US stock exchange, call at 4:30 p.m. ET (10:30 p.m. CEST

$OMDA (+0,3%)

$OMDA (+0,3%)

Omada Health (OMDA) reported Q4 2025 revenue of $76 million; net income was $5 million and adjusted EBITDA was $8 million. Gross margin in Q4 was 71 percent and non-GAAP gross margin was 73 percent. For the full year (FY) 2025, OMDA reported revenue of USD 260 million (up 53 percent), a net loss of USD 13 million and adjusted EBITDA of USD 6 million. FY gross margin was 66 percent, non-GAAP gross margin was 68 percent; cash and cash equivalents amounted to USD 222 million. Membership at year-end was 886,000 (up 55 percent). Operationally, OMDA highlighted GLP-1 activities (more than 150,000 members supported on GLP-1s) and announced GLP-1 Flex Care; it also launched AI tools OmadaSpark and Meal Map in 2025 and announced Omada for Cholesterol in February 2026. CEO Sean Duffy highlighted growth, profitability milestones and progress on GLP-1 support, AI capabilities and program enhancements. Outlook: For FY 2026, OMDA expects revenue of $312 million to $322 million and adjusted EBITDA of $7 million to $15 million.

Source: Reuters.com

Here are the latest figures on $OMDA (+0,3%) broken down with Gemini.

Key financial figures Q4 2025

- Turnover: USD 76 million

- Net income: USD 5 million (reaching the profit zone in the quarter)

- Adjusted EBITDA: USD 8 million

- Gross margin: 71% (non-GAAP: 73%)

Key financial figures for the full year (FY) 2025

- Turnover: USD 260 million (+53 % year-on-year)

- Net result: USD -13 million (net loss)

- Adjusted EBITDA: USD 6 million

- Gross margin: 66% (non-GAAP: 68%)

- Liquidity: USD 222 million (cash and cash equivalents)

Key operating figures & growth

- Number of members: 886,000 (+55 % year-on-year)

- GLP-1 sector: Over 150,000 members are supported with GLP-1 therapy.

Product development & strategy

- GLP-1 focus: Announcement of GLP-1 Flex Care for targeted support of this patient group.

- AI integration: Introduction of the OmadaSpark and Meal Map tools (2025).

- Portfolio expansion: Launch of Omada for Cholesterol in February 2026.

- Management focus: CEO Sean Duffy emphasizes transition to profitability, scaling through AI and expansion of GLP-1 companion programs.

Outlook FY 2026

- Sales forecast: USD 312 million to USD 322 million

- Adjusted EBITDA: USD 7 million to USD 15 million

$OMDA (+0,3%) Has anyone already pulled the ripcord or are you buying in installments?

Fingers crossed for the Q4 earnings on 05.03.2026 🤞🏻